S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:NTRP - Neurotrope Stock Price, Forecast & News

$0.78
-0.17 (-17.89 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$0.74
Now: $0.78
$0.99
50-Day Range
$0.66
MA: $0.80
$1.18
52-Week Range
$0.63
Now: $0.78
$8.40
Volume395,973 shs
Average Volume232,680 shs
Market Capitalization$10.19 million
P/E RatioN/A
Dividend YieldN/A
Beta1.97
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRP
CUSIPN/A
Phone973-242-0005

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.05 per share

Profitability

Net Income$-11,020,000.00

Miscellaneous

Employees6
Market Cap$10.19 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.


Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

How were Neurotrope's earnings last quarter?

Neurotrope Inc (NASDAQ:NTRP) released its earnings results on Tuesday, October, 30th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.05. View Neurotrope's Earnings History.

When is Neurotrope's next earnings date?

Neurotrope is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Neurotrope.

What price target have analysts set for NTRP?

2 analysts have issued 12-month price objectives for Neurotrope's shares. Their forecasts range from $1.00 to $16.00. On average, they anticipate Neurotrope's stock price to reach $8.50 in the next year. This suggests a possible upside of 989.7% from the stock's current price. View Analyst Price Targets for Neurotrope.

What is the consensus analysts' recommendation for Neurotrope?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neurotrope.

What are Wall Street analysts saying about Neurotrope stock?

Here are some recent quotes from research analysts about Neurotrope stock:
  • 1. According to Zacks Investment Research, "Neurotrope, Inc. is focused primarily on the development and commercialization of Alzheimer's disease therapeutic products related diagnostics. The Company develops and markets two product platforms, including a non-invasive diagnostic test for Alzheimer's disease and a drug candidate called bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage. Neurotrope, Inc. is based in Plantation, Florida. " (11/1/2019)
  • 2. Maxim Group analysts commented, "Neurotrope announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of Bryostatin-1 in acute lymphoblastic leukemia (ALL)." (2/5/2019)

Has Neurotrope been receiving favorable news coverage?

News articles about NTRP stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neurotrope earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Neurotrope.

Are investors shorting Neurotrope?

Neurotrope saw a decrease in short interest during the month of November. As of November 29th, there was short interest totalling 675,300 shares, a decrease of 5.4% from the November 14th total of 713,600 shares. Based on an average daily volume of 527,400 shares, the days-to-cover ratio is currently 1.3 days. Approximately 6.9% of the shares of the stock are sold short. View Neurotrope's Current Options Chain.

Who are some of Neurotrope's key competitors?

What other stocks do shareholders of Neurotrope own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Fibrocell Science (FCSC), Neos Therapeutics (NEOS), Alibaba Group (BABA), Canopy Growth (CGC), Intel (INTC), Iovance Biotherapeutics (IOVA), JD.Com (JD), Pieris Pharmaceuticals (PIRS) and Celgene (CELG).

Who are Neurotrope's key executives?

Neurotrope's management team includes the folowing people:
  • Dr. Charles S. Ryan, CEO & Director (Age 55)
  • Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 77)
  • Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 59)
  • Dr. Michael Ciraolo, Gen. Counsel & COO (Age 46)
  • Mr. Jeffrey Benison, Director of Corp. Communications

Who are Neurotrope's major shareholders?

Neurotrope's stock is owned by a number of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.49%) and Millennium Management LLC (0.27%). View Institutional Ownership Trends for Neurotrope.

Which major investors are buying Neurotrope stock?

NTRP stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Millennium Management LLC. View Insider Buying and Selling for Neurotrope.

How do I buy shares of Neurotrope?

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neurotrope's stock price today?

One share of NTRP stock can currently be purchased for approximately $0.78.

How big of a company is Neurotrope?

Neurotrope has a market capitalization of $10.19 million. The company earns $-11,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Neurotrope employs 6 workers across the globe.View Additional Information About Neurotrope.

What is Neurotrope's official website?

The official website for Neurotrope is http://www.neurotropebioscience.com/.

How can I contact Neurotrope?

Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]


MarketBeat Community Rating for Neurotrope (NASDAQ NTRP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  192 (Vote Underperform)
Total Votes:  354
MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Featured Article: What is a balanced fund?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel